Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

690 results about "Immune checkpoint" patented technology

Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. However, some cancers can protect themselves from attack by stimulating immune checkpoint targets.

Drug screening and disease model construction method for liver organoid

The invention provides a method for drug screening and disease model construction of liver organoid, relates to the technical field of medical research, and adopts multi-modal data acquisition, fusion and intelligent analysis and quantum computing processing to optimize comprehensive application of data, so that the richness, accuracy and analysis efficiency of the data are remarkably improved, and the risk of drug screening and disease model construction of liver organoid is reduced. Multi-source data of genomics, transcriptomics and the like are collected comprehensively, an accurate research system of immune-hepatic disease interaction based on organoid is constructed, an in-vivo complex immune-hepatic disease microenvironment can be highly simulated, the proportion and activation state of immune cells are accurately regulated and controlled in an in-vitro model, functional and phenotypic changes of the immune cells are monitored in real time, and the immune-hepatic disease interaction accuracy is improved. According to the present invention, the interaction mechanism between the immune cells and the liver organ cells is deeply revealed, such that the accurate information basis is provided for the accurate determination of the drug action target, the development of the innovative drug for the immune check point or tumor microenvironment regulation is easily achieved, and the pertinence and the success rate of the drug research and development are substantially improved.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof

The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and / or tumor-associated antigen; and (c) a binding site for human FcγRI, FcγRIIa and / or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and / or FcγRIII than to human FcγRIIb.
Owner:LINDIS BIOTECH GMBH

Lung adenocarcinoma prognosis risk prediction model and construction method and application thereof

The invention discloses a lung adenocarcinoma prognosis risk prediction model and a construction method and application thereof, and belongs to the technical field of biomedical detection. The lung adenocarcinoma (LUAD) prognosis model is successfully constructed by systematically analyzing the immune infiltration related gene (CAFRG) of tumor-associated fibroblasts (CAF), and the application value of the lung adenocarcinoma (LUAD) prognosis model in prediction of patient prognosis is verified. The CAFRG risk score is negatively related to the immune microenvironment score and is remarkably related to immune checkpoint gene expression, which suggests that a high-risk patient may have the characteristic of immune escape. Furthermore, based on TIDE tool analysis, the patients in the low-risk group have more active T cell immune response. The risk score is also closely related to the sensitivity of antitumor drugs, especially Doramapimod. Therefore, a new theoretical basis is provided for personalized treatment of lung adenocarcinoma, and a new direction is provided for future clinical research.
Owner:SUZHOU UNIV

Polynucleotide for expressing SARS-CoV-2 receptor binding domain, protein, viral vector and preparation method thereof, vaccine preparation and preparation method and application thereof

The invention provides polynucleotide for expressing an SARS-CoV-2 receptor binding domain, a protein, a viral vector and a preparation method thereof, a vaccine preparation and a preparation method and application thereof, and belongs to the field of biological medicine. The adeno-associated virus is utilized to simultaneously deliver an SARS-CoV-2 receptor binding domain (RBD) coding sequence with an optimized structure design and a plurality of shRNAs of a targeted immunomodulatory gene, so that tumor cells are over-expressed and an antigen RBD is efficiently presented, meanwhile, the RBD specific prestored immune response of a body is quickly awakened and enhanced, and the inhibiting effect of a PD1 / PD-L1 immune checkpoint on killing of T cells is relieved. Furthermore, the CpG1018 adjuvant is combined, and the CpG1018 and the AAV are packaged into the injectable hydrogel, so that the dual effects of enhancing the anti-tumor immune response and reducing the virus leakage infection are realized, and a strong tumor inhibition effect is shown in various solid tumors. The invention is expected to overcome the problems of limited antigen selection, poor universality and slow effect of the current tumor vaccine, and has a wide application prospect in the field of tumor immunotherapy.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL

Immunodetection method of multi-index immune checkpoint detection kit

The invention provides an immunodetection method of a multi-index immune checkpoint detection kit, which belongs to the technical field of immunodetection and comprises three main stages of sample preparation, immune reaction and data analysis. The method comprises the following steps: firstly, carrying out centrifugal separation to obtain a plasma sample, and preparing a fluorescent microsphere coupled capture antibody and biotin labeled detection antibody compound; then carrying out immune reaction, forming a sandwich type immune complex through specific binding, and adding streptavidin marked by phycoerythrin for signal amplification. Detecting a fluorescence signal by adopting a flow cytometer to obtain an original data matrix; a contribution feature vector, a utility feature vector and an expression feature matrix are extracted through a feature decomposition algorithm, and a deep learning model of a total-score-total structure is established for data analysis. Finally, a detection report containing a quantitative result, an importance score and reliability evaluation is generated, and the technical problem that in the prior art, the analysis accuracy of a multi-index immune checkpoint detection result is insufficient is solved.
Owner:QINGDAO RAISECARE BIOTECHNOLOGY CO LTD

Engineered probiotics for radiosensitization and tumor metabolism regulation as well as preparation method and application of engineered probiotics

PendingCN120884611ABacteriaAntibody ingredientsImmunoradiometryT cell
The invention belongs to the technical field of engineered probiotics, and particularly relates to engineered probiotics for radiosensitization and tumor metabolism regulation as well as a preparation method and application of the engineered probiotics. The engineering probiotics comprise probiotics and core-shell type metal nanoparticles which are loaded on the probiotics and are synthesized through a biological directional mineralization effect; the core of the core-shell type metal nanoparticle is a palladium element, and the outer layer of the core-shell type metal nanoparticle is a palladium element and a gold element. The engineering probiotics provided by the invention have excellent enzyme catalysis performance and can target and retain in tumor sites, and through the synergistic effect of all components in the engineering probiotics, adenosine metabolism is effectively inhibited, secretion of pro-inflammatory cytokines is enhanced, tumor microenvironment is promoted to be converted into an inflammatory state, up-regulation of immune checkpoints is inhibited, and the immune checkpoints are inhibited. And T cells are inhibited from being transformed into depletion phenotype and transformed into effect type from depletion type. After the SBRT and the immune checkpoint inhibitor are combined for use, the growth of tumors can be effectively inhibited, and the effect of enhancing immune radiotherapy is achieved.
Owner:HUAZHONG UNIV OF SCI & TECH

CAR-NK cell for knocking out KIR2DL5 targeting HER2, preparation method and application thereof

The invention provides a CAR-NK cell for knocking out KIR2DL5 targeting HER2 as well as a preparation method and application of the CAR-NK cell, and belongs to the technical field of genetic engineering.The CAR-NK cell is obtained by adopting a chimeric antigen receptor with HER2 as a target spot to infect an NK cell and then knocking out a KIR2DL5 gene; the chimeric antigen receptor taking the HER2 as the target spot comprises an HER2 single-chain antibody; the nucleic acid artificial sequence of the HER2 single-chain antibody is as shown in SEQ ID NO. 2. According to the application disclosed by the invention, the interaction of KIR2DL5-PVR is blocked by knocking out NK cell immune checkpoints, so that tumor immune escape is avoided, and the activity of killing tumor cells by CAR-NK cells is remarkably enhanced; according to the invention, by optimizing the nucleic acid artificial sequence of HER2, the secretion ability of CAR-NK cell factors, the tumor killing efficiency and the in-vivo inhibition effect on tumors can be improved.
Owner:SHANGHAI XINGRUIYIDA BIOTECHNOLOGY CO LTD

Inhibition of immune cells by immune checkpoint conjugates

The present invention provides cells (Immune Checkpoint Junction 'ICE' cells) having enhanced Immune Checkpoint Junction function. In some embodiments, the ICE cells have a PD-1 conjugation function (PD-1 conjugant cells). The ICE cells reduce adaptability and innate immunity when transplanted into a subject as compared to parental cells with corresponding unmodified immune checkpoint conjugation function. In some embodiments, the PD-1 zygote cells are low immune pluripotent (HIP) cells. In further embodiments, the HIP cell is type O blood (HIPO), rhesus monkey factor (Rh) negative (HIP-), or both type O and type Rh (HIPO-). In other embodiments, the PD-1 zygote cells have been derived or differentiated from HIP, HIP-, or HIPO-cells. In other embodiments, the ICE cell expresses a ligand that binds to a suppressive immune cell receptor selected from the group consisting of a LILRB1 zygote, a LILRB3 zygote, and a TIM3 zygote. In other embodiments, the ICE cell is a PD-1 zygote cell that also expresses a ligand that binds to another inhibitory immune cell receptor selected from the group consisting of CD47, truncated CD47, a LILRB1 zygote, a LILRB3 zygote, and a TIM3 zygote.
Owner:RGT UNIV OF CALIFORNIA

Photosensitizer chimera targeting PD-l1 protein, and preparation method therefor and use thereof

A photosensitizer chimera targeting PD-L1 protein, and a preparation method therefor and a use thereof. The photosensitizer chimera is of an X-R-G structure, wherein X is a photosensitizer unit, R is a linker, G is a polypeptide unit targeting PD-L1 protein, the photosensitizer is a porphyrin photosensitizer, and the excitation light wavelength of the photosensitizer is longer than 550 nm; the molar absorption coefficient at the maximum absorption wavelength longer than the wavelength of 550 nm is greater than 1000 M -1cm-1; the quantum yield of a triplet state exceeds 0.01; the linker is selected from the following structural formulas, wherein the amino side of the linker is connected to the photosensitizer unit, the carboxyl side of the linker is connected to the polypeptide unit, and n is an integer of 0-50; the binding constant of the polypeptide and h-PD-L1 is less than 20 µm. Combination therapy of immune checkpoint blockade and cytotoxicity induced by the photosensitive chimera based on photodegradation of PD-L1 protein in PD-1 / PD-L1 can cause stronger immune response than monotherapy, and thus the photosensitive chimera has great potential in enhancing antitumor therapy.
Owner:PEKING UNIV

Use of new immune checkpoint piezo1 pathway in tumor t-cell therapy

Provided is use of a new immune checkpoint PIEZO1 pathway in tumor T-cell therapy. A PIEZO1 inhibitor can be used for treating cancers, improving the killing ability of T cells, and improving the therapeutic effect of an immune checkpoint inhibitor.
Owner:INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES

TRMT61A and application of TRMT61A inhibitor tetramethylthiuram disulfide in tumor immunotherapy

The invention provides application of TRMT61A and its inhibitor tetramethylthiuram disulfide in tumor immunotherapy, and relates to the technical field of biological medicine, clinical research proves that RNA m1A methyltransferase TRMT61A is highly expressed in tumor tissues and is related to poor prognosis of tumor patients, and can be used as one of tumor therapy targets. Meanwhile, high expression of the TRMT61A is related to poor prognosis of a tumor patient receiving anti-PD-1 immunotherapy, and after anti-PD-1 antibody immunotherapy is carried out on the patient with low TRMT61A expression level in the tumor of the patient, pathological complete relief is easier. Tetramethylthiuram disulfide inhibits TRMT61A, inhibits m1A modification regulation of TRMT61A on PD-L1 mRNA, increases PD-L1 protein expression, and is combined with a PD-1 antibody drug to significantly enhance the immunotherapy effect of the anti-PD-1 immune checkpoint drug in treating malignant tumors.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY (GUANGZHOU SEVERE MATERNAL TREATMENT CENTER GUANGZHOU ROUJI HOSPITAL)

Immune and tumour cells expression of vista in a panel of cancer indications

InactiveEP4560319A1Disease diagnosisMultiplexTumour tissue
The present invention provides multiplex assays for improved scoring of tumour tissues stained with an immune checkpoint protein such as VISTA. Methods of ranking multiple tumour tissues and of diagnosing cancer patients are also provided. The methods disclosed are also useful for identifying patient responsive to anticancer therapy.
Owner:PIERRE FABRE MEDICAMENT SAS

Function-enhanced iPSC-derived NK cell and application thereof

The invention provides a function-enhanced iPSC (induced pluripotent stem cell)-derived NK (natural killer) cell and application thereof, and also provides a recombinant induced pluripotent stem cell which is prepared by a method comprising the following steps: taking an initial induced pluripotent stem cell as a starting cell, blocking / inhibiting the expression of PD-1 and over-expressing human interleukin 15. The invention also provides the function-enhanced NK cell derived from the iPSC and a construction method of the pluripotent stem cell capable of producing the function-enhanced NK cell. The function-enhanced NK cell derived from the pluripotent stem cells can automatically secrete IL-15, so that the function-enhanced NK cell has lasting activity keeping ability and tumor killing ability in vitro and in vivo, and meanwhile, the activity of the cell is enhanced due to the fact that the expression of PD-1 protein is blocked. The function-enhanced NK cell overcomes tumor cell tolerance and immune escape caused by expression of an immune checkpoint PD-1, and further function enhancement is shown.
Owner:HANGZHOU JIYUAN GENE TECH CO LTD

Application of spirolactone in preparation of synergist of immune checkpoint inhibitor

The invention relates to the technical field of biological medicine, and particularly discloses application of spirolactone in preparation of a synergist of an immune checkpoint inhibitor. The application finds that spirolactone can enhance the effect of the immune checkpoint inhibitor on treating liver cancer, has no toxic or side effect on animals, and improves the tumor killing ability of infiltrating NK cells. Animal experiments show that the progress of the liver cancer can be remarkably inhibited by combining the spirolactone with the immune checkpoint inhibitor, and the tumor killing capability of infiltrating NK cells can be improved by combining administration, so that the spirolactone can be used as an auxiliary medicine for clinically improving or enhancing the immune checkpoint to treat the liver cancer (HCC).
Owner:GUANGDONG GENERAL HOSPITAL

Application of combination of oncopoxvirus and immune checkpoint PD-L1 / TDO2 inhibitor in preparation of antitumor drugs

The invention belongs to the field of antitumor drug compositions, and particularly relates to application of combination of oncopoxvirus and an immune checkpoint PD-L1 / TDO2 inhibitor in preparation of antitumor drugs. T lymphocytes, macrophages and the like can be chemotactically infiltrated into TME in a mode of combination of the oncopoxvirus rVV-CCL5, the immune checkpoint PD-L1 inhibitor and the immune checkpoint TDO2 inhibitor; a cold tumor is converted into a hot tumor, so that the immunosuppression state of TME is effectively reversed, and the anti-tumor effect of the PD-L1 / TDO2 inhibitor is enhanced.
Owner:FIRST PEOPLES HOSPITAL OF YUNNAN PROVINCE

Drug delivery nano-vesicle based on self-activated T cell membrane as well as preparation method and application of drug delivery nano-vesicle

The invention relates to the technical field of biology, in particular to a drug delivery nano-vesicle based on an autoactivated T cell membrane as well as a preparation method and an application of the drug delivery nano-vesicle. The drug delivery nano-vesicle comprises a cationic lipid type nano-particle, diaminobenzimidazole embedded in the cationic lipid type nano-particle, and a primary activated T cell membrane positioned on the outer surface of the cationic lipid type nano-particle. In the invention, the STING agonist diaminobenzimidazole (diABZI) is used for activating congenital and adaptive immune response, enhancing expression and secretion of IFN-beta by tumor cells and DC cells, inducing DC maturation and promoting T cells to infiltrate tumor; the activated T cell membrane simultaneously expressing multiple immune checkpoints competitively relieves the inhibition effect of multiple immune checkpoints, enhances the tumor killing ability of T cells, and realizes the synergistic anti-tumor curative effect.
Owner:THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY

Nucleic acid aptamer agonist conjugate as well as preparation method and application thereof

The invention provides a nucleic acid aptamer agonist conjugate as well as a preparation method and application thereof. The nucleic acid aptamer agonist conjugate is prepared by coupling a nucleic acid aptamer, a connexon and an STING agonist, the nucleic acid aptamer agonist conjugate can be used as a medicine to recognize a target spot on the surface of a tumor cell in a targeted manner and enter the cell to start a cGAS-STING signal channel so as to realize an anti-tumor effect. The variety of STING agonists and the variety of connexons are also screened, so that the aptamer agonist conjugate not only has the advantages of easiness in transmembrane and cell entry, strong tumor permeability, long half-life period, small toxic and side effects and the like, but also has a strong inhibition effect on triple-negative breast cancer. The aptamer agonist conjugate can also be combined with an immune checkpoint blocking therapy to further realize long-acting and efficient inhibition of tumor growth.
Owner:HANGZHOU INSTITUTE OF MEDICAL SCIENCES CHINESE ACADEMY OF SCIENCES

Anti-VSIG4 and Anti-siglec-7 inhibitory antibody against intermolecular interaction between VSIG4 and siglec-7

To create an antibody that inhibits an immune checkpoint function based on interaction between VSIG4 and Siglec-7 and exhibits antitumor activity, and to provide an anti-tumor immune response activator which includes the antibody as an active ingredient.SOLUTION: The present invention provides an anti-tumor immune response activator including an antibody that inhibits intermolecular interaction between VSIG4 and Siglec-7 or a functional fragment thereof.SELECTED DRAWING: Figure 9
Owner:THE UNIV OF TOKYO

Enhanced combination immune checkpoint inhibition therapy utilizing rnai

PCT designated stage expiredWO2025117786A1Organic active ingredientsAntibody ingredientsBRD4Double strand
Aspects of the disclosure relate to methods for enhanced combination immune checkpoint inhibition therapy utilizing RNAi, including by intratumoral administration of chemically-modified double stranded nucleic acid molecules directed against genes encoding PD-1, BRD4, CTLA-4, TIGIT, and / or CBL-B.
Owner:PHIO PHARMACEUTICALS CORP

Identification of T-cell trafficking genes and uses thereof for increasing infiltration of T-cells into solid tumors

Disclosed are compositions, kits, and methods for identifying genes that are involved in T-cell trafficking. In particular, the compositions, kits, and methods may be used to identify genes involved in T-cell trafficking and / or infiltration into tumors such as genes that encode immune checkpoint regulators and / or stimulatory agents. The disclosed compositions, kits, and methods utilize the Sleeping Beauty® transposon system in a mouse tumor model to identify genes that are involved in T-cell trafficking and infiltration into tumors. The genes identified in the disclosed methods may provide immunotherapy targets in the tumor microenvironment. The identified genes may be utilized in order to develop therapies that enhance T-cell trafficking and infiltration into tumors and / or T-cell killing of tumors such as in chimeric antigen receptor (CAR) T cell therapies.
Owner:THE UNIVERSITY OF IOWA RESEARCH

Immune checkpoint inhibitor and therapeutic agent for immune checkpoint-related disease

Provided are an immune checkpoint inhibitor containing as an active ingredient a substance that inhibits the interaction of integrin and immunosuppressive receptor (referred to hereinafter as LILR) B3 and a therapeutic agent for immune checkpoint-related disease containing as an active ingredient a substance that inhibits the interaction of integrin and LILRB3.
Owner:TOHOKU UNIV

Preparation method and application of targeted pancreatic cancer immune checkpoint diagnosis and treatment integrated nanoprobe

The invention relates to a preparation method and application of a targeted pancreatic cancer immune checkpoint diagnosis and treatment integrated nanoprobe, which can realize integration of sonodynamic therapy and MRI imaging of pancreatic cancer cells with high expression of VISTA, realize targeted SDT therapy of pancreatic cancer and visual evaluation of the therapeutic effect, have good biological safety, and can be applied to diagnosis and treatment of pancreatic cancer cells with high expression of VISTA. SDT visual treatment of targeted pancreatic cancer is realized at a cellular level, and SDT combined immunotherapy of pancreatic cancer is realized at an animal level. The method comprises the following steps: (1) preparing Fe3O4 nanoparticles by using a solvothermal method; (2) preparing Fe3O4 (at) SiO2 nano particles; (3) preparing Fe3O4 (at) SiO2 (at) TiO2 nano particles; (4) preparing Fe3O4 (at) TiO2 by adopting an alkaline hydrothermal corrosion auxiliary crystallization method; and (5) modifying the nanoprobe with a VISTA antibody through an electrostatic adsorption method, and finally successfully constructing the garland-shaped nanoprobe.
Owner:THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV

Cell bionic nanoparticles as well as construction method and application thereof

ActiveCN119139348AReduce immune response levelsGreat clinical valueSenses disorderPowder deliveryInflammatory factorsAutoimmune condition
The invention belongs to the technical field of cell bionic nano-drugs, and particularly discloses a cell bionic nano-particle as well as a construction method and application thereof. And performing simple ultrasonic fusion on the target cell membrane and the hydrophobic nano-core to obtain the cell bionic nano-particles. The bionic nano-cell can effectively inherit and simulate functional protein on the surface of a source cell membrane, systematically replace functions of the source cell in physiological and pathological processes, such as inflammatory factor adsorption, migration factor adsorption and the like, interfere and inhibit the disease process from the cellular mechanism, regulate and control cell composition and immune microenvironment of a focus part, and improve the immune function of the source cell membrane. The medicine does not need to be additionally carried. Aiming at the related pathogenesis of immune tolerance deficiency, the invention innovatively provides a therapeutic strategy for constructing immune tolerance. The homology and inherent immunosuppressive ability of tumor cells to the focus part of the autoimmune disease are reversely used, immune tolerance of the focus part based on immune checkpoints is reconstructed, meanwhile, target cells are replaced to adsorb autoimmune antibodies, and the immune response level is reduced.
Owner:KUNMING MEDICAL UNIVERSITY

Composition for regulating production of interfering ribonucleic acid

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.
Owner:WYVERN PHARMACEUTICALS INC

Methods for early detection of cancer

Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of cancers through genomic and epigenomic profiling, including immune checkpoint regulators such as programmed death ligand 1 (PDL-1). Using methods and compositions described herein, specific and sensitive detection of biomarkers of interest is provided. Such biomarkers are indicative of disease pathogenesis, which provides opportunity for selection of treatment, including treatment regimes directed at overcoming resistance mechanisms.
Owner:GUARDANT HEALTH INC

Chimeric inhibitory signaling modulators

Described herein are fusion proteins comprising an extracellular domain of an immune checkpoint receptor and a cytoplasmic domain of an activating receptor. Also described herein are fusion proteins comprising a cytoplasmic domain of an immune checkpoint receptor and an extracellular domain of an activating receptor. The present disclosure further provides methods of use of such fusion proteins.
Owner:THE GENERAL HOSPITAL CORP

Hydrogel-based delivery system and method for inducing three-level lymphatic structure in tumor and enhancing immune checkpoint blocking

The present invention provides a system for drug delivery that utilizes a hydrogel to deliver a bioactive agent to stimulate three-level lymphatic structure formation within a mature tumor and enhance immune checkpoint blocking. Provided herein is an injectable hydrogel that can stimulate the formation of immune structures within a tumor, improve cancer prognosis and therapeutic response. The invention provides application of the system to treatment of cancer. Methods of making the drug delivery system are also provided.
Owner:THE UNIVERSITY OF HONG KONG +1

Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatment of such disease

ActiveUS12140594B2Digestive systemDisease diagnosisDiseasePancreas Ductal Adenocarcinoma
The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of βig-h3 protein in a blood sample wherein the serum level of βig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that βig-h3 can be directly detected in the blood sample and βig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of βig-h3 protein, for use in the treatment of PDAC. The inventors found that βig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing βig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response. Thus, neutralizing βig-h3 which acts as a novel immunological check-point target in PDAC therefore allows to restore beneficial anti-tumor immunity in PDAC.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4

Method for determining resistance to immune checkpoint inhibitors

PCT designated stage expiredWO2024254435A2Microbiological testing/measurementDisease diagnosisHaplogroupCell biology
Provided are methods for determining responsiveness to immune checkpoint inhibition. The methods involve determining a mitochondrial haplogroup for an individual who has been diagnosed with cancer. Based on the determination of the mitochondrial haplogroup, an immune checkpoint inhibition therapy can be selected for the individual with improved likelihood of efficacy compared to selection of an immune checkpoint inhibition therapy selected without the mitochondrial haplogroup analysis. The mitochondrial haplogroup analysis can be performed prior to initiating an immune checkpoint therapy.
Owner:NEW YORK UNIV